OakChart

Upstream Bio Inc

UPBHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 10:35 AM ET

3.37-0.01 (-0.30%)
2026-11-11 16:35 CET
Market cap
185.13 USD m
Revenue, TTM
2.87 USD m
Net income, TTM
-163.94 USD m
Free cash flow, TTM
-168.39 USD m
EPS diluted, TTM
-3.01
P/E
-
Compare

Price

UPB against its 20, 50 and 200-day averages
2050200beatearnings
5.0010.0015.001.4M2.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26UPBclose 3.3720-day 3.1350-day 4.38200-day 8.173.37

90.0% under the 52-week high of 33.68 on 14 Jan 2026. 52-week low 2.68 on 27 Oct 2026. Last 15 sessions, 43.4% high to low

Profile

UPB
52-week range, 2% of the way up
2.6833.68

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

IndexRUT
Employees75
IPOOct 11, 2024
Beta1.57
ATR, 14d0.34
Rel volume0.57
Short float10.20%
Insider own36.44%
Inst own71.45%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap184.58M
Enterprise Value-22.00M
Income-163.94M
Sales2.87M
Book/sh4.27
Cash/sh3.79
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees75
IPOOct 11, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S64.31
P/B0.79
P/C0.89
P/FCF-
EV/EBITDA-
EV/Sales-7.66
Quick Ratio20.45
Current Ratio20.45
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.01
EPS next Y-2.81
EPS next Q-0.70
EPS this Y-7.69%
EPS next Y1.73%
EPS next 5Y-3.10%
EPS past 3/5Y-81.53% -
Sales past 3/5Y33.04% -
EPS Y/Y TTM-31.89%
Sales Y/Y TTM2.54%
EPS Q/Q-20.15%
Sales Q/Q-42.17%
EarningsNov 10 BMO
EPS/Sales Surpr.-2.54% -27.11%

Ownership

Insider Own36.44%
Insider Trans-0.05%
Inst Own71.45%
Inst Trans4.49%
ROA-51.46%
ROE-53.53%
ROIC-70.05%
Gross Margin92.86%
Oper. Margin-6115.99%
Profit Margin-5712.33%
SMA207.51%
SMA50-23.06%
SMA200-58.73%
Trades-

Technical

Shs Outstand54.81M
Shs Float34.81M
Short Float10.20%
Short Ratio3.95
Short Interest3.55M
52W High33.68 -89.99%
52W Low2.68 25.75%
Volatility13.30% 11.61%
ATR (14)0.34
RSI (14)44.24
Beta1.57
Rel Volume0.57
Avg Volume897.88K
Volume106,027

Performance

Perf Week-8.92%
Perf Month-5.07%
Perf Quarter-51.23%
Perf Half Y-64.00%
Perf YTD-87.59%
Perf Year-85.83%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.50
Target Price21.00
Prev Close3.38
Price3.37
Change %-0.30%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Jun 12, 2026DowngradeJJP MorganOverweight → Neutral$8+137.4%
Jun 03, 2026InitiatedHH.C. WainwrightBuy$36+968.2%
Mar 27, 2026DowngradeEEvercore ISIOutperform → In-line$15+345.1%
Dec 18, 2025InitiatedMMizuhoOutperform$51+1,413.4%
Nov 18, 2025InitiatedEEvercore ISIOutperform$40+1,086.9%
Oct 14, 2025InitiatedTTruistBuy$47+1,294.7%
Nov 05, 2024InitiatedWWilliam BlairOutperform
Nov 05, 2024InitiatedTTD CowenBuy
Nov 05, 2024InitiatedPPiper SandlerOverweight$75+2,125.5%
Nov 05, 2024InitiatedJJP MorganOverweight$38+1,027.6%

Peers

Mkt cap
TickerCompanyMkt cap
GENBGenerate Biomedicines Inc1.75B
ATTOAttovia Therapeutics Inc772.55M
ZURAZura Bio Ltd136.78M
TRAXFirst Tracks Biotherapeutics Inc2.16B
ANABAnaptysBio Inc1.46B
EVMNEvommune Inc309.03M
SYRESpyre Therapeutics Inc9.92B
ALMSAlumis Inc875.64M
ARQTArcutis Biotherapeutics Inc3.58B
IMNMImmunome Inc2.24B

Insider trading

latest 14 of 15
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
GRAY MICHAELCFO and COOSep 16 '26Sale5.498534,68327,942Sep 17 04:05 PM
Ambrose AllisonGeneral CounselSep 16 '26Sale5.494852,66315,563Sep 17 04:05 PM
Deykin AaronChief Medical OfficerSep 16 '26Sale5.498954,91432,302Sep 17 04:05 PM
Sutherland Everett RandChief Executive OfficerSep 16 '26Sale5.492,09511,50268,717Sep 17 04:05 PM
Houghton AdamChief Business OfficerSep 16 '26Sale5.497003,84322,901Sep 17 04:05 PM
GRAY MICHAELCFO and COOJun 16 '26Sale6.108535,20328,795Jun 17 04:05 PM
Sutherland Everett RandChief Executive OfficerJun 16 '26Sale6.102,09512,78070,812Jun 17 04:05 PM
Houghton AdamChief Business OfficerJun 16 '26Sale6.107004,27023,601Jun 17 04:05 PM
Deykin AaronChief Medical OfficerJun 16 '26Sale6.108955,46033,197Jun 17 04:05 PM
Ambrose AllisonGeneral CounselJun 16 '26Sale6.104772,91016,048Jun 17 04:05 PM
GRAY MICHAELCFO and COOMar 16 '26Sale9.298527,91529,648Mar 17 05:03 PM
Deykin AaronChief Medical OfficerMar 16 '26Sale9.298948,30532,687Mar 17 05:02 PM
Sutherland Everett RandChief Executive OfficerMar 16 '26Sale9.292,09319,44472,907Mar 17 05:00 PM
Ambrose AllisonGeneral CounselMar 16 '26Sale9.294754,41316,525Mar 17 05:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 122
  • Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress (GlobeNewswire) -5.59%
  • These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch)
  • Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 (GlobeNewswire)
  • Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP (GlobeNewswire)
  • Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress (GlobeNewswire)
  • Loading…
  • Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 (GlobeNewswire)
  • Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 (GlobeNewswire) -8.51%
  • Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire) +5.24%
  • Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference (GlobeNewswire) -6.38%
  • Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
  • Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference (GlobeNewswire)
  • Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls (The Fly) -11.44%
  • Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.750-0.731-0.5550.400.558
2026Q22026-08-11-0.729-0.726-0.7280.770.569
2026Q12026-05-13-0.750-0.750-0.7471.031.036
2025Q42026-03-26-0.775-0.735-0.7860.670.588
2025Q32025-11-05-0.630-0.782-0.6260.680.655
2025Q22025-08-06-0.740-0.610-0.7430.940.324
2025Q12025-05-06-0.510-0.485-0.5080.570.334
2024Q42025-03-12-0.433-0.559-0.4070.610.384
2024Q32024-11-07-6.958-6.930-0.3920.610.454
2024Q22024-08-28-11.180--1.20--
2026Q4---0.702--0.468
2027Q1---0.710--0.205
2027Q2---0.709--0.215
2027Q3---0.622--0.215
2027Q4---0.637--0.215
2028Q1---0.725--0.461

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-5.581-8.027-1.4252.372.15
2025FY-2.623-2.595-2.6602.852.68
2026FY--2.875--2.65
2027FY--2.829--1.25
2028FY--2.931--3.79
2029FY--3.256--9.21
2030FY--2.934--50.66

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-096110.460.000.80
2026Q4S2026-10-276010.520.000.80
2026Q4S2026-10-256020.520.000.80
2026Q4S2026-09-076130.520.000.80
2026Q4S2026-08-316130.520.000.80
2026Q4S2026-08-216120.530.000.80
2026Q4S2026-08-137120.580.000.88
2026Q4S2026-08-127210.610.001.00
2026Q4S2026-08-117110.470.000.88
2026Q4S2026-07-277000.440.000.88
2026Q4S2026-06-117200.440.000.88
2026Q4S2026-06-026200.510.000.88
2026Q4S2026-05-135200.510.000.88
2026Q4S2026-03-265010.440.000.88

Estimate history

EPS, annual-0.445-0.714-1.425-2.664-3.0123
Period2022202320242025TTM
EPS, quarterly-0.392-0.407-0.508-0.743-0.626-0.786-0.747-0.728-0.752
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1.2122.382.372.8542.87
Period2022202320242025TTM
Sales, quarterly0.6070.6130.5660.9370.6830.6681.0340.7730.395
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual53.60353.60353.60354.23854.811
Period2022202320242025MRQ
Shares, quarterly53.60353.60353.64153.7985454.23854.4254.77154.811
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue2.872.852.372.381.21
Cost of Goods Sold Incl. D&A0.200.190.090.060.01
Gross Profit2.672.672.282.321.21
Selling, General and Administrative Excl. Other178.19163.0380.0542.4325.11
Research and Development149.43136.8162.9731.8018.66
Other Operating Expense0.000.000.000.000.00
Operating Income-175.53-160.36-77.76-40.11-23.91
Interest Expense0.000.000.000.000.00
Unusual Expense0.000.00-2.86-15.530.08
Net Income Before Taxes-163.94-143.44-62.81-20.54-23.87
Income Taxes0.000.000.000.000.00
Consolidated Net Income-163.94-143.44-62.81-20.54-23.87
Net Income From Continuing Operations-163.94-143.44-62.81-20.54-23.87
Net Income-163.94-143.44-76.39-38.26-23.87
EPS (Recurring)-2.99-2.66-1.46-0.92-0.44
EPS (Basic, Before Extraordinaries)-3.01-2.66-1.43-0.71-0.45
EPS (Diluted)-3.01-2.66-1.43-0.71-0.45
EBITDA-175.32-160.17-77.67-40.05-23.90
Non-Operating Income (Expense)11.5916.9212.104.050.12
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense15.8510.336.003.431.28
Price To Sales Ratio100.60512.30371.83--
Gross Margin92.8693.4196.2497.4899.42
Operating Margin-6,115.99-5,618.82-3,281.18-1,685.46-1,972.69
Net Margin-5,712.33-5,026.03-3,223.42-1,607.35-1,969.31
Shares Outstanding54.8154.2453.6053.6053.60
Market Capitalization185.13185.13881.13917.57-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.400.771.030.670.680.940.570.61
Cost of Goods Sold Incl. D&A0.050.050.050.060.030.060.040.05
Gross Profit0.350.720.980.610.650.880.520.56
Selling, General and Administrative Excl. Other43.7343.0944.6046.7838.4945.2332.5426.88
Research and Development36.6136.0936.5640.1732.9837.8725.8021.77
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-43.38-42.37-43.62-46.17-37.83-44.35-32.01-26.32
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-41.19-39.70-40.59-42.46-33.75-39.97-27.27-21.24
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-41.19-39.70-40.59-42.46-33.75-39.97-27.27-21.24
Net Income From Continuing Operations-41.19-39.70-40.59-42.46-33.75-39.97-27.27-21.24
Net Income-41.19-39.70-40.59-42.46-33.75-39.97-27.27-21.79
EPS (Recurring)-0.75-0.73-0.75-0.78-0.63-0.74-0.51-0.41
EPS (Basic, Before Extraordinaries)-0.75-0.73-0.75-0.79-0.63-0.74-0.51-0.41
EPS (Diluted)-0.75-0.73-0.75-0.79-0.63-0.74-0.51-0.41
EBITDA-43.33-42.32-43.57-46.11-37.80-44.29-31.97-26.27
Non-Operating Income (Expense)2.192.673.023.714.094.384.745.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.344.354.652.512.592.602.632.09
Price To Sales Ratio100.60119.57147.20515.96362.43216.82--
Gross Margin87.5993.5395.2691.4795.4693.9292.4092.01
Operating Margin-10,982.03-5,480.98-4,218.09-6,911.23-5,539.39-4,732.87-5,656.01-4,293.31
Net Margin-10,428.35-5,136.09-3,925.63-6,356.14-4,941.14-4,265.31-4,818.02-3,554.65
Shares Outstanding54.8154.7754.4254.2454.0053.8053.6453.60
Market Capitalization185.13376.59489.781,467.151,014.04590.65328.28881.13

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments341.51470.45109.8117.05
Short Term Receivables2.321.180.240.41
Inventories0.000.000.000.00
Other Current Assets7.977.536.950.84
Total Current Assets351.80479.16117.0018.31
Net Property, Plant & Equipment1.782.370.200.16
Total Investments and Advances0.190.190.000.00
Intangible Assets0.000.000.00-
Other Assets0.000.000.000.01
Total Assets353.77481.72117.2018.48
Short Term Debt Incl. Current Port. of LT Debt0.720.700.040.09
Accounts Payable2.734.041.990.71
Other Current Liabilities10.015.994.484.06
Total Current Liabilities13.4510.746.514.86
Long Term Debt0.551.130.000.01
Provision for Risks Charges0.000.000.000.00
Other Liabilities0.000.002.876.95
Total Liabilities14.0011.879.3911.81
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.00230.94112.82
Common Equity339.77469.85-123.13-106.16
Total Shareholders Equity339.77469.85107.816.67
Accumulated Minority Interest0.000.000.000.00
Total Equity339.77469.85107.816.67
Total Liabilities & Stockholders Equity353.77481.72117.2018.48
Book Value Per Share6.268.77-2.30-1.98
Tangible Book Value Per Share6.268.77-2.30-1.98
Full-Time Employees755235-
Price to Book Ratio0.79-5.50-5.72-
Return on Assets-34.34-20.97-30.27-
Return on Equity-35.43-21.74-35.88-
Return on Invested Capital-42.15-13.34-19.05-357.57
Quick Ratio26.1544.6317.963.77
Current Ratio26.1544.6317.963.77

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-163.94-143.44-62.81-20.54-23.87
Depreciation0.200.190.090.060.01
Other Funds (Non Cash)16.629.391.67-13.141.43
Funds from Operations-147.12-133.86-61.05-33.62-22.43
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-21.220.591.87-4.303.41
Cash from Operating Activities-168.33-133.28-59.17-37.93-19.02
Capital Expenditures-0.05-0.17-0.51-0.14-0.08
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments139.34-93.31-58.97-82.700.00
Purchase of Investments-119.41-385.88-290.61-128.990.00
Sale Or Maturity of Investments258.75292.56231.6346.290.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities139.28-93.48-59.48-82.84-0.08
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock4.302.44418.91129.559.96
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock4.302.44418.91129.559.96
Proceedsfrom Stock Options2.280.16418.75129.439.96
Issuance or Reduction of Debt, Net0.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities4.302.44418.91129.559.96
Net Change in Cash-24.75-224.31300.258.78-9.14
Free Cash Flow-168.39-133.44-59.68-38.07-19.10
Preferred Dividends (Cash Flow)-0.00--0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments207.37261.31294.58341.51372.43393.58
Short Term Receivables1.472.152.612.322.312.64
Inventories0.000.000.000.000.000.00
Other Current Assets35.8016.1419.097.9714.2822.05
Total Current Assets244.63279.60316.28351.80389.02418.27
Net Property, Plant & Equipment1.171.381.581.781.982.06
Total Investments and Advances0.190.190.190.190.190.19
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets245.99281.17318.05353.77391.19420.52
Short Term Debt Incl. Current Port. of LT Debt0.730.730.720.720.720.71
Accounts Payable2.382.311.712.733.952.55
Other Current Liabilities8.846.9511.2310.017.247.67
Total Current Liabilities11.969.9913.6713.4511.9110.93
Long Term Debt0.060.230.390.550.700.85
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities12.0210.2114.0614.0012.6111.78
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity233.97270.96304.00339.77378.58408.74
Total Shareholders Equity233.97270.96304.00339.77378.58408.74
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity233.97270.96304.00339.77378.58408.74
Total Liabilities & Stockholders Equity245.99281.17318.05353.77391.19420.52
Book Value Per Share4.274.955.596.267.017.60
Tangible Book Value Per Share4.274.955.596.267.017.60
Full-Time Employees---75--
Price to Book Ratio0.791.241.443.872.481.32
Return on Assets-51.46-44.61-40.50-34.34-39.18-
Return on Equity-53.53-46.05-41.83-35.43-40.80-
Return on Invested Capital-17.60-14.64-13.34-12.48-8.90-9.76
Quick Ratio20.4527.9923.1426.1532.6738.27
Current Ratio20.4527.9923.1426.1532.6738.27

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-41.19-39.70-40.59-42.46-33.75-39.97
Depreciation0.050.050.050.060.050.04
Other Funds (Non Cash)4.084.474.044.022.581.75
Funds from Operations-37.06-35.18-36.50-38.38-31.12-38.17
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-17.17-0.44-11.357.758.88-1.06
Cash from Operating Activities-54.23-35.62-47.85-30.63-22.24-39.24
Capital Expenditures0.000.000.00-0.05-0.06-0.05
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments22.1815.7642.4059.0048.2512.82
Purchase of Investments-15.77-50.94-14.42-38.28-24.46-57.08
Sale Or Maturity of Investments37.9566.7056.8297.2872.7169.90
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities22.1815.7642.4058.9448.1912.77
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.072.530.601.100.760.61
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.072.530.601.100.760.61
Proceedsfrom Stock Options0.002.080.000.200.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.072.530.601.100.760.61
Net Change in Cash-31.98-17.33-4.8529.4126.71-25.85
Free Cash Flow-54.23-35.62-47.85-30.68-22.30-39.29

Revenue breakdown

Pharmaceutical Preparations2024: 2.37M 2025: 2.85M
United States2024: 2.37M 2025: 2.85M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.20%3.6M34.8M847.77K
2026-10-1512.87%4.5M34.8M708.87K
2026-09-3012.10%4.5M37.3M577.95K
2026-09-1512.04%4.5M37.3M599.09K
2026-08-3110.98%4.1M37.3M610.00K
2026-08-1410.77%4.0M37.3M615.53K
2026-07-3110.07%3.6M36.2M573.61K
2026-07-159.99%3.6M36.2M589.03K
2026-06-3011.33%4.1M36.2M617.76K
2026-06-1510.76%3.9M36.2M665.46K
2026-05-2910.03%3.6M36.3M722.83K
2026-05-159.36%3.4M36.3M987.18K
2026-04-3011.12%3.2M29.0M1.29M
2026-04-1510.43%3.0M29.0M1.31M
2026-03-3111.94%3.4M28.8M1.32M
2026-03-1316.64%4.8M28.6M1.25M
2026-02-2714.31%4.1M28.6M1.14M
2026-02-1312.36%3.5M28.6M880.77K
2026-01-3012.51%3.2M25.5M551.33K
2026-01-1513.56%3.5M25.5M518.12K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.004.902.200.0003.000.000.896-0.0090.001
call5.000.000.500.054.25975.000.000.417-0.0470.002
call7.500.003.000.055.78624.000.000.357-0.0610.002
call10.000.000.050.103.69842.000.000.069-0.0140.001
call12.500.000.550.074.23976.000.000.063-0.0150.001
call15.000.004.900.094.79310.000.000.058-0.0170.001
call17.500.004.000.085.01115.000.000.056-0.0160.001
put2.500.000.050.050.0001650.000.0000.0000.000
put5.000.104.900.6028.78055.000.00-0.583-0.0500.002
put7.501.606.502.7516.13773.000.00-0.643-0.0650.002
put10.004.109.003.1417.0766.000.00-0.932-0.0140.001
put12.506.6011.504.7017.7371.000.00-0.938-0.0140.001
put15.009.0014.000.0018.2590.000.00-0.942-0.0150.001
put17.5011.5016.500.0018.6900.000.00-0.945-0.0150.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-06SCHEDULE 13G/ASEC
2026-10-29SCHEDULE 13G/ASEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-018-KCurrent report2026-09-01SEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-30SCHEDULE 13GSEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-108-KCurrent report2026-06-09SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-04-16ARSAnnual report to security holders. 2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090027.60K5
2026-080000
2026-070000
2026-060030.62K5
2026-050000
2026-040000
2026-030046.57K5
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC14.94%
ORBIMED ADVISORS LLC10.46%
NORGES BANK6.93%
BlackRock, Inc.6.90%
Decheng Capital LLC5.01%
Enavate Sciences GP, LLC4.52%
VANGUARD CAPITAL MANAGEMENT LLC3.45%
MILLENNIUM MANAGEMENT LLC2.10%
D. E. Shaw & Co., Inc.1.90%
JPMORGAN CHASE & CO1.86%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.65%
Fidelity Small Cap Growth Fund2.52%
Fidelity Stock Selector Small Cap Fund2.43%
Fidelity Series Small Cap Opportunities Fund1.77%
iShares Russell 2000 ETF1.69%
Select Health Care Portfolio1.46%
Fidelity Small Cap Growth K6 Fund1.27%
Fidelity Advisor Biotechnology Fund1.27%
Federated Hermes Kaufmann Fund0.79%
Fidelity Advisor Health Care Fund0.74%

OakChart. UPB. Cached 15 minutes.